Hikma制药公司股份在2025年11月6日下跌了14.1%,因为制造业延迟,预计增长率较低。 Hikma Pharmaceuticals shares fell 14.1% on Nov. 6, 2025, on lower growth forecasts due to manufacturing delays.

2025年11月6日星期四,希克马制药公司股票下跌了14.1%至1,522英镑,在经过订正的中期展望之后,交易量猛增,达到1.66亿股,比平均数高出7,989%。 Hikma Pharmaceuticals shares dropped 14.1% to GBX 1,522 on Thursday, November 6, 2025, amid a surge in trading volume to 166 million shares—7,989% above average—following a revised medium-term outlook. 由于Bedford制造设施的延迟,该公司降低了其注射分数的增长预测,将全面运营推至2027年底。 The company lowered its growth forecasts for its injectables division due to delays at its Bedford manufacturing facility, pushing full operations to late 2027. 尽管下降,分析师仍维持“Buy”共识评级,目标价格为2,615英镑,而Hikma重申其2025年全年指导准则。 Despite the decline, analysts maintain a "Buy" consensus rating and a target price of GBX 2,615, while Hikma reaffirmed its full-year 2025 guidance. 股票价格仍然低于50天和200天的移动平均数,表明有下降势头。 The stock’s price remains below its 50-day and 200-day moving averages, suggesting downward momentum.